Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypercholesterolemia
Intervention: ezetimibe (+) simvastatin (Drug); atorvastatin (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
An efficacy and Safety Study of ezetimibe (+)simvastatin compared to atorvastatin
(ezetimibe/simvastatin) at week 6 in primary hypercholesterolemia patients in Korea.
Clinical Details
Official title: A Multicenter, Randomized, Open-Label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin vs. Atorvastatin in Patients With Primary Hypercholesterolemia.
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: LDL-C lowering efficacy
Secondary outcome: safety
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- clinical diagnosis of hypercholesterolemia,
- LDL-C >/= 130 mg/dL but
- NCEP ATP III guideline
Exclusion Criteria:
- Hypersensitivity to HMG-CoA inhibitor or Ezetimibe
Locations and Contacts
Additional Information
Starting date: November 2005
Ending date: October 2007
Last updated: December 23, 2007
|
